We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Owens & Minor (OMI) to Report Q1 Earnings: What's in Store?
Read MoreHide Full Article
Owens & Minor, Inc. (OMI - Free Report) is scheduled to report first-quarter 2021 results on May 5, before market open.
In the last-reported quarter, the company’s earnings of $1.14 beat the Zacks Consensus Estimate by 32.56%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, the average beat being 88.38%.
Let’s see how things have shaped up prior to this announcement.
Factors to Note
Global Products Business
Owens & Minor, during its February update, announced the installation of new N95 production lines in its U.S.-based manufacturing facilities. Further, it added non-woven fabric manufacturing in Lexington, NC facility. It also continued to expand its isolation and surgical gown production capacity. The company has been putting in efforts to optimize the operational process to maximize output of the production lines.
With the unrelenting spread of COVID-19 across the globe through the first-quarter months, the demand for its personal protective equipment (“PPE”) line has reached sky high. The latest developments accordingly are likely to have significantly boosted the company’s top line in the first quarter.
Global Solutions Business
Owens & Minor has been witnessing rebound in demand for elective procedures in the past few months. This improvement mainly started to take place following a dismal first-half 2020 performance within medical distribution.
The company undertook a few measures like expanding its low unit of measure warehouse infrastructure system, improving inventory planning process and algorithms and enhancing data management services offering through myOM and QSight. It has also improved B2B and B2C offerings in home healthcare business. We expect these developments to get reflected in the first-quarter results.
The Estimate Picture
For first-quarter 2021, the Zacks Consensus Estimate for total revenues of $2.29 billion implies an improvement of 7.9% from the prior-year reported figure.
The consensus estimate for earnings per share is pegged at 97 cents, implying a massive improvement from the prior-year reported figure of 4 cents.
What Our Model Suggests
Our proven model predicts an earnings beat for Owens & Minor this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) increases the chances of an earnings beat. That is exactly the case here as you will see below.
Earnings ESP: Owens & Minor has an Earnings ESP of +2.41%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Other Stocks Worth a Look
Here are a few medical stocks worth considering, as these also have the right combination of elements to beat on earnings this reporting cycle.
Chimerix, Inc. (CMRX - Free Report) has an Earnings ESP of +42.7% and a Zacks Rank of 2, at present.
Inogen, Inc (INGN - Free Report) has an Earnings ESP of +46.43% and is a Zacks #2 Ranked stock.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Image: Bigstock
Owens & Minor (OMI) to Report Q1 Earnings: What's in Store?
Owens & Minor, Inc. (OMI - Free Report) is scheduled to report first-quarter 2021 results on May 5, before market open.
In the last-reported quarter, the company’s earnings of $1.14 beat the Zacks Consensus Estimate by 32.56%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, the average beat being 88.38%.
Let’s see how things have shaped up prior to this announcement.
Factors to Note
Global Products Business
Owens & Minor, during its February update, announced the installation of new N95 production lines in its U.S.-based manufacturing facilities. Further, it added non-woven fabric manufacturing in Lexington, NC facility. It also continued to expand its isolation and surgical gown production capacity. The company has been putting in efforts to optimize the operational process to maximize output of the production lines.
Owens & Minor, Inc. Price and EPS Surprise
Owens & Minor, Inc. price-eps-surprise | Owens & Minor, Inc. Quote
With the unrelenting spread of COVID-19 across the globe through the first-quarter months, the demand for its personal protective equipment (“PPE”) line has reached sky high. The latest developments accordingly are likely to have significantly boosted the company’s top line in the first quarter.
Global Solutions Business
Owens & Minor has been witnessing rebound in demand for elective procedures in the past few months. This improvement mainly started to take place following a dismal first-half 2020 performance within medical distribution.
The company undertook a few measures like expanding its low unit of measure warehouse infrastructure system, improving inventory planning process and algorithms and enhancing data management services offering through myOM and QSight. It has also improved B2B and B2C offerings in home healthcare business. We expect these developments to get reflected in the first-quarter results.
The Estimate Picture
For first-quarter 2021, the Zacks Consensus Estimate for total revenues of $2.29 billion implies an improvement of 7.9% from the prior-year reported figure.
The consensus estimate for earnings per share is pegged at 97 cents, implying a massive improvement from the prior-year reported figure of 4 cents.
What Our Model Suggests
Our proven model predicts an earnings beat for Owens & Minor this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) increases the chances of an earnings beat. That is exactly the case here as you will see below.
Earnings ESP: Owens & Minor has an Earnings ESP of +2.41%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Other Stocks Worth a Look
Here are a few medical stocks worth considering, as these also have the right combination of elements to beat on earnings this reporting cycle.
DENTSPLY SIRONA Inc. (XRAY - Free Report) has an Earnings ESP of +11.36% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Chimerix, Inc. (CMRX - Free Report) has an Earnings ESP of +42.7% and a Zacks Rank of 2, at present.
Inogen, Inc (INGN - Free Report) has an Earnings ESP of +46.43% and is a Zacks #2 Ranked stock.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>